海南海藥(000566.SZ):漢闊生物年產100噸美羅培南項目及相關配套設施獲批覆產
格隆匯 9 月 1日丨海南海藥(000566.SZ)公佈,公司於2020 年3 月22 日召開第九屆董事會第四十四次會議,審議通過了《關於簽署重組構建鹽城醫藥化工全產業鏈平台合作協議的議案》。收購完成後,江蘇漢闊生物有限公司(“漢闊生物”)成為公司的間接控股子公司。
漢闊生物因配合鹽城市對轄區內所有化工生產企業開展安全環保整治工作已於2019 年3 月起臨時停產。漢闊生物於近日收到《鹽城市人民政府辦公室關於江蘇漢闊生物有限公司復產事項的批覆》,批覆主要內容如下:
“原則同意漢闊生物年產100噸美羅培南項目及相關配套設施恢復生產”
“漢闊生物要落實安全環保主體責任,進一步細化復產前各項準備工作,確保復產過程安全、環保可控;企業復產後,要嚴格遵守國家、省、市相關規定,規範開展生產經營活動,積極配合相關部門監督檢查。”
收到《批覆》後,漢闊生物將嚴格按照政府要求,有序推進各項復產工作,並結合市場環境和自身實際經營情況逐步復產。此次復產將補強公司培南類產品的生產能力,增強公司培南類核心品種的成本控制、原材料掌控、產品質量管理等能力。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.